IRCT20201107049296N1 IRCT 2021-08-31 Iran University of Medical Sciences Evaluation of the effect of oral curcumin on liver enzymes and liver T2*MRI Evaluation of the effect of oral curcumin on liver enzymes and liver T2*MRI in patients with major and intermediate thalassemia 2021-09-01 anticipated 80 Complete https://irct.ir/trial/52137 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: - A number plate or sheet is made for the total number of people in the case and control groups (numerical code from 1 to N). - All plaques are placed in an opaque bag. - Considering that half of the subjects are as Intervention group population and the other half are as the control group population, Half of the plaques are removed from the bag by drawing lots (based on the probabilistic sampling principles). The number of these plaques is considered as the code of the people receiving the real medicine and this code is also included on the real medicine packages. Obviously, the other codes will be related to the controls and حplacebo packages, Blinding description: In this double-blind study, only the main executor of the project will know the type of medication each patient receives, and by the end of the test, neither patient nor physician will know which patient is receiving medication or placebo. This will be done through the coding of patients and drugs. Meaning of the codes will be recognizable only to the main executor of the project. 3 Thalassemia. Intervention 1: Intervention group: receive 500 mg curcumin tablet (Razak pharmaceutical product) every 12 hours. Intervention 2: Control group: receive placebo pill every 12 hours. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information.